Avalo Therapeutics Inc AVTX.OQ AVTX.O is expected to show a fall in quarterly revenue when it reports results on November 5 (estimated) for the period ending September 30 2025
LSEG's mean analyst estimate for Avalo Therapeutics Inc is for a loss of $1.62 per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had risen by about 0.5% in the last three months.
Wall Street's median 12-month price target for Avalo Therapeutics Inc is $35.00, about 76.1% above its last closing price of $8.35
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -1.40 | -1.40 | -1.92 | Missed | -36.7 |
Mar. 31 2025 | -1.40 | -1.39 | -1.25 | Beat | 9.9 |
Dec. 31 2024 | 0.25 | -0.39 | -7.95 | Missed | -1,929.8 |
Sep. 30 2024 | -1.10 | -1.19 | -1.25 | Missed | -5 |
Jun. 30 2024 | -6.70 | -6.70 | -14.07 | Missed | -110 |
Mar. 31 2024 | -1.18 | -1.18 | -1.41 hundred | Missed | -11,849.2 |
Dec. 31 2023 | -4.80 | -1.16 hundred | Missed | -2,321.1 | |
Sep. 30 2023 | -2.64 hundred | -26.40 | Beat | 90 |
This summary was machine generated August 8 at 17:40 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。